Skip to main content
. 2021 Apr 14;60:28–45. doi: 10.1016/j.cytogfr.2021.03.006

Table 5.

Rationales for Treatment with Hydroxyurea in Patients with COVID-19.

graphic file with name fx6_lrg.gif